Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-d-glucuronidase (heparanase)

Glycobiology

Volumn 22, Issue 1, 2012, Pages 35-55

  Gandhi, Neha S ^a,b   Freeman, Craig ^b   Parish, Christopher R ^b   Mancera, Ricardo L ^a,b,c  

^a CURTIN UNIVERSITY   (Australia)

^b Biology and Environment   (Australia)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

glycol split; glycosidase; heparanase; heparin; molecular dynamics

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; CARBOHYDRATE; GLUCOSAMINE; GLUCURONIC ACID; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARAN SULFATE; HEPARANASE; HEPARIN DERIVATIVE; INDOLE; MORPHOLINE; PI 88; PIPERIDINE; PYRIDINE; TRISACCHARIDE; XYLAN ENDO 1,3 BETA XYLOSIDASE;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWN REGULATION; DRUG BINDING SITE; ENERGY; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HYDROGEN BOND; MATHEMATICAL ANALYSIS; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURAL BIOINFORMATICS; SULFATION;

AMINO ACID SEQUENCE; BINDING SITES; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CATALYTIC DOMAIN; CONSERVED SEQUENCE; GLUCURONIDASE; GLYCOSAMINOGLYCANS; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PHYLOGENY; PROTEIN BINDING; SEQUENCE ALIGNMENT; STRUCTURAL HOMOLOGY, PROTEIN; SURFACE PROPERTIES; THERMODYNAMICS;

EID: 83255163230     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwr095     Document Type: Article

References (157)

1. Almond A, Sheehan JK. 2003. Predicting the molecular shape of polysacchar-ides from dynamic interactions with water. Glycobiology. 13:255-264. (Pubitemid 36603285)
2. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucl Acids Res. 25:3389-3402. (Pubitemid 27359211)
3. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N. 2010. ConSurf 2010: Calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucl Acids Res. 38 (Suppl):W529-W533.
4. Bame KJ. 2001. Heparanases: Endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology. 11:91R-98R. (Pubitemid 32660349)
5. Barash U, Cohen-Kaplan V, Arvatz G, Gingis-Velitski S, Levy-Adam F, Nativ 0, Shemesh R, Ayalon-Sofer M, Ilan N, Vlodavsky I. 2010. A novel human heparanase splice variant, T5, endowed with protumorigenic charac eristics. FASEB J. 24:1239-1248.
6. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. 2010. Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis. FEBS J. 277:3890-3903.
7. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky 1. 1987. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood. 70:551-557. (Pubitemid 17142944)
8. Berendsen HJC, Postma JPM, Gunsteren WFV, DiNola A, Haak JR. 1984. Molecular dynamics with coupling to an external bath. J Chem Phys. 81:3684-3690.
9. Berezin C, Glaser F, Rosenberg J, Paz I, Pupko T, Fariselli P, Casadio R, Ben-Tal N. 2004. ConSeq: The identification of functionally and structurally important residues in protein sequences. Bioinformatics. 20:1322-1324. (Pubitemid 38807587)
10. Bisio A, Mantegazza A, Urso E, Naggi A, Torri G, Viskov C, Casu B. 2007. High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase. Semin Thromb Hemost. 33:488-495. (Pubitemid 47105738)
11. Bitomsky W, Wade RC. 1999. Docking of glycosaminoglycans to heparin-binding proteins: Validation for aFGF, bFGF, and antithrombin and application to IL-8. J Am Chem Soc. 121:3004-3013. (Pubitemid 29189745)
12. Boeckmann B, Bairoch A, Apweiler R, Blatter M-C, Estreicher A, Gasteiger E, Martin MJ, Michoud K, O'Donovan C, Phan I, et al. 2003. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucl Acids Res. 31:365-370. (Pubitemid 36157284)
13. Bowie JU, Luthy R, Eisenberg D. 1991. A method to identify protein sequences that fold into a known three-dimensional structure. Science. 253:164-170. (Pubitemid 21917131)
14. Brylinski M, Skolnick J. 2008. A threading-based method (FINDSITE) for ligand-binding site prediction and functional annotation. Proc Natl Acad Sci USA. 105:129-134.
15. Brylinski M, Skolnick J. 2009. FINDSITE: A threading-based approach to ligand homology modeling. PLoS Comput Biol. 5:e1000405.
16. Brylinski M, Skolnick J. 2010. Comparison of structure-based and threading-based approaches to protein functional annotation. Proteins. 78:118-134.
17. Cantu D, Nerinckx W, Reilly PJ. 2008. Theory and computation show that Asp463 is the catalytic proton donor in human endoplasmic reticulum alpha-(1-<2)-mannosidase I. Carbohydr Res. 343:2235-2242.
18. Cao H, Yu B. 2005. Synthesis of a S-linked heparan sulfate trisaccharide as the substrate mimic of heparanase. Tetrahedron Lett. 46:4337-4340. (Pubitemid 40725416)
19. Case DA, Cheatham Iii TE, Darden T, Gohlke H, Luo R, Merz Jr KM, Onufriev A, Simmerling C, Wang B, Woods RJ. 2005. The Amber biomo-lecular simulation programs. J Comput Chem. 26:1668-1688.
20. Casu B, Vlodavsky I, Sanderson RD. 2008. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb. 36:195-203.
21. Combet C, Blanchet C, Geourjon C, Deleage G. 2000. NPS@: Network protein sequence analysis. Trends Biochem Sci. 25:147-150. (Pubitemid 30122428)
22. Coombe DR, Stevenson SM, Kinnear BF, Gandhi NS, Mancera RL, Osmond RI, Kett WC. 2008. Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosaminoglycans. 2. Biochemical analyses. Biochemistry. 47:4863-4875. (Pubitemid 351574993)
23. Coutinho PM, Dowd MK, Reilly PJ. 1997. Automated docking of monosaccharide substrates and analogues and methyl alpha-acarviosinide in the glu-coamylase active site. Proteins. 27:235-248. (Pubitemid 27113719)
24. Coutinho PM, Dowd MK, Reilly PJ. 1998. Automated docking of oc-(1,4)-and oc-(1,6)-linked llucosyl trisaccharides in the glucoamylase active site. Ind Eng Chem Res. 37:2148-2157. (Pubitemid 128717965)
25. Czjzek M, Ben David A, Bravman T, Shoham G, Henrissat B, Shoham Y 2005. Enzyme-substrate complex structures of a GH39 beta-xylosidase from Geobacillus stearothermophilus. JMolBiol. 353:838-846. (Pubitemid 41457385)
26. Davies G, Henrissat B. 1995. Structures and mechanisms of glycosyl hydrolases. Structure. 3:853-859.
27. Davies MN, Toseland CP, Moss DS, Flower DR. 2006. Benchmarking pK(a) prediction. BMC Biochem. 7:18.
28. Davies GJ, Wilson KS, Henrissat B. 1997. Nomenclature for sugar-binding subsites in glycosyl hydrolases. Biochem J. 321 (Pt 2):557-559. (Pubitemid 27056509)
29. Debeche T, Bliard C, Debeire P, O'Donohue MJ. 2002. Probing the catalyti-cally essential residues of the alpha-L-arabinofuranosidase from Thermobacillus xylanilyticus. Protein Eng. 15:21-28. (Pubitemid 34184338)
30. Dempsey LA, Plummer TB, Coombes SL, Platt JL. 2000. Heparanase expression in invasive trophoblasts and acute vascular damage. Glycobiology 10:467-475. (Pubitemid 30216088)
31. Dominguez R, Souchon H, Lascombe M, Alzari PM. 1996. The crystal structure of a family 5 endoglucanase mutant in complexed and uncomplexed forms reveals an induced fit activation mechanism. J Mol Biol. 257:1042-1051. (Pubitemid 26117089)
32. Driguez H. 2001. Thiooligosaccharides as tools for structural biology. Chembiochem. 2:311-318. (Pubitemid 33722572)
33. Dvir H, Harel M, McCarthy AA, Toker L, Silman I, Futerman AH, Sussman JL. 2003. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4:704-709. (Pubitemid 36974756)
34. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. 1997. Empirical scoring functions. I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des. 11:425-445. (Pubitemid 127505895)
35. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, Vlodavsky I. 2001. Heparanase as mediator of angiogenesis: Mode of action. FASEB J. 15:1661-1663.
36. Eric FP, Thomas DG, Conrad CH, Gregory SC, Daniel MG, Elaine CM, Thomas EF. 2004. UCSF chimera-A visualization system for exploratory research and analysis. J Comput Chem. 25:1605-1612.
37. Esko JD, Linhardt RJ. 2009. Proteins that bind sulfated glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of glycobiology. New York: CSHL Press.
38. Fairbanks MB, Mildner AM, Leone JW, Cavey GS, Mathews WR, Drong RF, Slightom JL, Bienkowski MJ, Smith CW, Bannow CA, et al. 1999. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem. 274:29587-29590.
39. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C, Johnstone K, Karoli T, Davis K, Copeman E, et al. 2007. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost. 33:557-568.
40. Ferro V, Hammond E, Fairweather JK. 2004. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem. 4:693-702. (Pubitemid 38961234)
41. Ferro DR, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V, Perly B, Sinay P, Petitou M, Choay J. 1990. Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res. 195:157-167.
42. Fort S, Varrot A, Schulein M, Cottaz S, Driguez H, Davies GJ. 2001. Mixed-linkage cellooligosaccharides: A new class of glycoside hydrolase inhibitors. Chembiochem. 2:319-325. (Pubitemid 33722573)
43. FRED 2008a. FRED (Fast Rigid Exhaustive Docking). Santa Fe, NM: Openeye Scientific Software.
44. FRED. 2008b. OMEGA C++ Toolkit. Sante Fe, NM: OpenEye Scientific Software, Inc.
45. Freeman C, Parish CR. 1998. Human platelet heparanase: Purification, characterization and catalytic activity. Biochem J, 330: 1341-1350. (Pubitemid 28162014)
46. Frishman D, Argos P. 1996. Incorporation of non-local interactions in protein secondary structure prediction from the amino acid sequence. Protein Eng. 9:133-142. (Pubitemid 26119294)
47. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, Vlodavsky I, Ilan N. 2009. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 69:1758-1767.
48. Fux L, Ilan N, Sanderson RD, Vlodavsky I. 2009. Heparanase: Busy at the cell surface. Trends Biochem Sci. 34:511-519.
49. Gandhi NS, Coombe DR, Mancera RL. 2008. Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosaminoglycans. 1. Molecular modeling studies. Biochemistry. 47:4851-4862. (Pubitemid 351574992)
50. Gandhi NS, Mancera RL. 2009. Free energy calculations of glycosaminogly-can-protein interactions. Glycobiology. 19:1103-1115.
51. Gandhi NS, Mancera RL. 2010. Heparin/heparan sulphate-based drugs. Drug Discov Today. 15:1058-1069.
52. Gandhi NS, Mancera RL. 2011. Molecular dynamics simulations of CXCL-8 and its interactions with a receptor peptide, heparin fragments, and sulfated linked cyclitols. J Chem Inf Model. 51:335-358.
53. Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DR, Fogel LJ, Freer ST. 1995. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming. Chem Biol. 2:317-324.
54. Gilat D, Hershkoviz R, Goldkorn I, Cahalon L, Korner G, Vlodavsky I, Lider O. 1995. Molecular behavior adapts to context: Heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J Exp Med. 181:1929-1934.
55. Goldenberg O, Erez E, Nimrod G, Ben-Tal N. 2009. The ConSurf-DB: Pre-calculated evolutionary conservation profiles of protein structures. Nucl Acids Res. 37:D323-D327.
56. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. 2005. H++: A server for estimating pKas and adding missing hydrogens to macromol-ecules. Nucl Acids Res. 33:W368-W371. (Pubitemid 44529945)
57. Gozalbes R, Mosulen S, Carbajo RJ, Pineda-Lucena A. 2009. Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors. J Comput Aided Mol Des. 23:555-569.
58. Graham LD, Underwood PA. 1996. Comparison of the heparanase enzymes from mouse melanoma cells, mouse macrophages, and human platelets. Biochem Mol Biol Int. 39:563-571. (Pubitemid 26254603)
59. Guermeur Y, Geourjon C, Gallinari P, Deleage G. 1999. Improved performance in protein secondary structure prediction by inhomogeneous score combination. Bioinformatics. 15:413-421. (Pubitemid 29312629)
60. Henrissat B, Bairoch A. 1993. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem J. 293:781-788. (Pubitemid 23244564)
61. Henrissat B, Bairoch A. 1996. Updating the sequence-based classification of glycosyl hydrolases. Biochem J. 316:695-696. (Pubitemid 26182174)
62. Hill AD, Reilly PJ. 2008. Computational analysis of glycoside hydrolase family 1 specificities. Biopolymers. 89:1021-1031.
63. Hovel K, Shallom D, Niefind K, Belakhov V, Shoham G, Baasov T, Shoham Y, Schomburg D. 2003. Crystal structure and snapshots along the reaction pathway of a family 51 alpha-L-arabinofuranosidase. EMBO J. 22:4922-4932. (Pubitemid 37222014)
64. Huey R, Morris GM, Olson AJ, Goodsell DS. 2007. A semiempirical free energy force field with charge-based desolvation. J Comput Chem. 28:1145-1152. (Pubitemid 46506716)
65. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. 1999. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med. 5:803-809. (Pubitemid 29318615)
66. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, Parish CR. 2000. Identification of active-site residues of the pro-metastatic endo-glycosidase heparanase. Biochemistry. 39:15659-15667. (Pubitemid 32038227)
67. Ihrcke NS, Parker W, Reissner KJ, Platt JL. 1998. Regulation of platelet heparanase during inflammation: Role of pH and proteinases. J Cell Physiol. 175:255-267. (Pubitemid 28198205)
68. Irimura T, Nakajima M, Nicolson GL. 1986. Chemically modified heparins as inhibitors of heparan sulfate-specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry. 25:5322-5328. (Pubitemid 17016547)
69. Ishida K, Hirai G, Murakami K, Teruya T, Simizu S, Sodeoka M, Osada H. 2004. Structure-based design of a selective heparanase inhibitor as an anti-metastatic agent. Mol Cancer Ther. 3:1069-1077. (Pubitemid 39295004)
70. Ishida K, Wierzba MK, Teruya T, Simizu S, Osada H. 2004. Novel heparan sulfate mimetic compounds as antitumor agents. Chem Biol. 11:367-377. (Pubitemid 39403876)
71. Isorna P, Polaina J, Latorre-Garcia L, Canada FJ, Gonzalez B, Sanz-Aparicio J. 2007. Crystal structures of Paenibacillus polymyxa beta-glucosidase B complexes reveal the molecular basis of substrate specificity and give new insights into the catalytic machinery of family I glycosidases. J Mol Biol. 371:1204-1218. (Pubitemid 47198251)
72. Jain S, Drendel WB, Chen ZW, Mathews FS, Sly WS, Grubb JH. 1996. Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat Struct Biol. 3:375-381. (Pubitemid 26112636)
73. Jalali-Heravi M, Asadollahi-Baboli M, Shahbazikhah P. 2008. QSAR study of heparanase inhibitors activity using artificial neural networks and Levenberg-Marquardt algorithm. Eur J Med Chem. 43:548-556. (Pubitemid 351324887)
74. Johnson DJ, Li W, Adams TE, Huntington JA. 2006. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrom-bin activation. EMBO J. 25:2029-2037.
75. Johnstone KD, Karoli T, Liu L, Dredge K, Copeman E, Li CP, Davis K, Hammond E, Bytheway I, Kostewicz E, et al. 2010. Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. J Med Chem. 53:1686-1699.
76. Jones DT, Taylor WR, Thornton JM. 1992. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci. 8:275-282.
77. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. 1983. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 79:926-935.
78. Katoh K, Toh H. 2008. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform. 9:286-298. (Pubitemid 351890825)
79. Kelley LA, Sternberg MJ. 2009. Protein structure prediction on the Web: A case study using the Phyre server. Nat Protoc. 4:363-371.
80. King RD, Sternberg MJ. 1996. Identification and application of the concepts important for accurate and reliable protein secondary structure prediction. Protein Sci. 5:2298-2310. (Pubitemid 26384468)
81. Kitago Y, Karita S, Watanabe N, Kamiya M, Aizawa T, Sakka K, Tanaka I. 2007. Crystal structure of Cel44A, a glycoside hydrolase family 44 endo-glucanase from Clostridium thermocellum. J Biol Chem. 282:35703-35711. (Pubitemid 350277103)
82. Kongsted J, Ryde U, Wydra J, Jensen JH. 2007. Prediction and rationalization of the pH dependence of the activity and stability of family 11 xylanases. Biochemistry. 46:13581-13592. (Pubitemid 350209954)
83. Koropatkin NM, Smith TJ. 2010. SusG: A unique cell-membrane-associated alpha-amylase from a prominent human gut symbiont targets complex starch molecules. Structure. 18:200-215.
84. Kudchadkar R, Gonzalez R, Lewis KD. 2008. PI-88: A novel inhibitor of angiogenesis. Expert Opin Investig Drugs. 17:1769-1776.
85. Lai NS, Simizu S, Morisaki D, Muroi M, Osada H. 2008. Requirement of the conserved, hydrophobic C-terminus region for the activation of heparanase. Exp Cell Res. 314:2834-2845.
86. Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I, Ilan N. 2005. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem. 280:20457-20466. (Pubitemid 40776745)
87. Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, Naroditsky I, Ilan N, Doweck I, Vlodavsky I. 2010. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem. 285:28010-28019.
88. Luthy R, Bowie JU, Eisenberg D. 1992. Assessment of protein models with three-dimensional profiles. Nature. 356:83-85.
89. Marchetti D, Liu S, Spohn WC, Carson DD. 1997. Heparanase and a synthetic peptide of heparan sulfate-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate. J Biol Chem. 272:15891-15897. (Pubitemid 27265568)
90. McKenzie EA. 2007. Heparanase: A target for drug discovery in cancer and inflammation. Br J Pharmacol. 151:1-14. (Pubitemid 46675998)
91. McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, et al. 2000. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun. 276:1170-1177.
92. Mertz B, Hill AD, Mulakala C, Reilly PJ. 2007. Automated docking to explore subsite binding by glycoside hydrolase family 6 cellobiohydrolases and endoglucanases. Biopolymers. 87:249-260. (Pubitemid 350075356)
93. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z. 2006. Development of hepara-nase inhibitors for anti-cancer therapy. Curr Med Chem. 13:2101-2111. (Pubitemid 44132602)
94. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 19:1639-1662. (Pubitemid 128590223)
95. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 30:2785-2791.
96. Mosulen S, Orti L, Bas E, Carbajo RJ, Pineda-Lucena A. 2011. Production of heparanase constructs suitable for nuclear magnetic resonance and drug discovery studies. Biopolymers. 95:151-160.
97. Mukherjee S, Roy A, Zhang Y. 2010. PSFloger: An on-line service system for identifying protein structural and functional analogs. Ann Arbor, MI: University of Michigan.
98. Mulakala C, Reilly PJ. 2002. Understanding protein structure-function relationships in Family 47 alpha-1,2-mannosidases through computational docking of ligands. Proteins. 49:125-134. (Pubitemid 34983180)
99. Mulloy B, Forster MJ, Jones C, Davies DB. 1993. N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem J. 293 (Pt 3):849-858. (Pubitemid 23244575)
100. Naggi A. 2005. Glycol-splitting as a device for modulating inhibition of growth factors and heparanase by heparin and heparin derivatives. In: Hari GG, Robert JL, Charles AH, editors. Chemistry and Biology of Heparin and Heparan Sulfate. Amsterdam, The Netherlands: Elsevier Science. p. 461-481.
101. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R, Vlodavsky I. 2005. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem. 280:12103-12113.
102. Nakajima M, Irimura T, Di Ferrante N, Nicolson GL. 1984. Metastatic melanoma cell heparanase: Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem. 259:2283-2290. (Pubitemid 14190344)
103. Nakajima M, Irimura T, Nicolson GL. 1988. Heparanases and tumor metastasis. J Cell Biochem. 36:157-167.
104. Nam KH, Lee WH, Rhee KH, Hwang KY. 2010. Structural characterization of the bifunctional glucanase-xylanase CelM2 reveals the metal effect and substrate-binding moiety. Biochem Biophys Res Commun. 391:1726-1730.
105. Nasser NJ, Avivi A, Shushy M, Vlodavsky I, Nevo E. 2007. Cloning, expression, and characterization of an alternatively spliced variant of human heparanase. Biochem Biophys Res Commun. 354:33-38. (Pubitemid 46123194)
106. Nasser NJ, Nevo E, Shafat I, Ilan N, Vlodavsky I, Avivi A. 2005. Adaptive evolution of heparanase in hypoxia-tolerant Spalax: Gene cloning and identification of a unique splice variant. Proc Natl Acad Sci USA. 102:15161-15166. (Pubitemid 41513352)
107. Nielsen JE, McCammon JA. 2003a. Calculating pKa values in enzyme active sites. Protein Sci. 12:1894-1901. (Pubitemid 37022812)
108. Nielsen JE, McCammon JA. 2003b. On the evaluation and optimization of protein X-ray structures for pKa calculations. Protein Sci. 12:313-326. (Pubitemid 36120344)
109. Okada Y, Yamada S, Toyoshima M, Dong J, Nakajima M, Sugahara K. 2002. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis: Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem. 277:42488-42495. (Pubitemid 35285615)
110. Olsson M, Søndergaard C, Rostkowski M, Jensen J. 2011. PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput. 7(2):525-537.
111. Paes G, Skov LK, O'Donohue MJ, Remond C, Kastrup JS, Gajhede M, Mirza O. 2008. The structure of the complex between a branched pentasaccharide and Thermobacillus xylanilyticus GH-51 arabinofuranosi-dase reveals xylan-binding determinants and induced fit. Biochemistry. 47:7441-7451. (Pubitemid 351991023)
112. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. 1999. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 59:3433-3441. (Pubitemid 29334505)
113. Parish CR, Freeman C, Hulett MD. 2001. Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta. 1471:M99-M108. (Pubitemid 32206686)
114. Peterson SB, Liu J. 2010. Unraveling the specificity of heparanase utilizing synthetic substrates. J Biol Chem. 285:14504-14513.
115. Pikas DS, Li JP, Vlodavsky I, Lindahl U. 1998. Substrate specificity of hepar-anases from human hepatoma and platelets. J Biol Chem. 273:18770-18777. (Pubitemid 28366261)
116. Pupko T, Bell RE, Mayrose I, Glaser F, Ben-Tal N. 2002. Rate4Site: An algorithmic tool for the identification of functional regions in proteins by surface mapping of evolutionary determinants within their homologues. Bioinformatics. 18:S71-S77. (Pubitemid 41185639)
117. Rambaut A. 2006a. FigTree, A Graphical Viewer of Phylogenetic Trees. Edinburgh: Institute of Evolutionary Biology. p. FigTree is designed as a graphical viewer of phylogenetic trees and as a program for producing publication-ready figures.
118. Rambaut A. 2006b. FigTree, A Graphical Viewer of Phylogenetic Trees and as a Program for Producing publication-ready Figures. http://tree.bio.ed.ac. uk/software/figtree/.
119. Rost B, Sander C. 1993. Prediction of protein secondary structure at better than 70% accuracy. J Mol Biol. 232:584-599. (Pubitemid 23251181)
120. Rost B, Sander C. 1994. Combining evolutionary information and neural networks to predict protein secondary structure. Proteins. 19:55-72. (Pubitemid 24151484)
121. Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: A unified platform for automated protein structure and function prediction. Nat Protoc. 5:725-738.
122. Ryckaert J-P, Ciccotti G, Berendsen HJC. 1977. Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J Comput Phys. 23:327-341.
123. Sali A, Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 234:779-815. (Pubitemid 24007801)
124. Sato M, Amemiya K, Hayakawa S, Munakata H. 2008. Subcellular localization of human heparanase and its alternative splice variant in COS-7 cells. Cell Biochem Funct. 26:676-683.
125. Sattelle BM, Almond A. 2010. Less is more when simulating unsulfated gly-cosaminoglycan 3D-structure: Comparison of GLYCAM06/TIP3P, PM3-CARB1/TIP3P, and SCC-DFTB-D/TIP3P predictions with experiment. J Comput Chem. 31:2932-2947.
126. Schmidt A, Schlacher A, Steiner W, Schwab H, Kratky C. 1998. Structure of the xylanase from Penicillium simplicissimum. Protein Sci. 7:2081-2088. (Pubitemid 28495794)
127. Sharp KA, Nicholls A, Sridharan S. 1998. DelPhi. New York: Department of Biochemistry and Molecular Biophysics, Columbia University.
128. Shen MY, Sali A. 2006. Statistical potential for assessment and prediction of protein structures. Protein Sci. 15:2507-2524. (Pubitemid 44771688)
129. Shi J, Blundell TL, Mizuguchi K. 2001. FUGUE: Sequence-structure hom-ology recognition using environment-specific substitution tables and structure-dependent gap penalties. J Mol Biol. 310:243-257. (Pubitemid 32619966)
130. Simizu S, Ishida K, Osada H. 2004. Heparanase as a molecular target of cancer chemotherapy. Cancer Sci. 95:553-558. (Pubitemid 39089634)
131. Simizu S, Ishida K, Wierzba MK, Osada H. 2004. Secretion of heparanase protein is regulated by glycosylation in human tumor cell lines. J Biol Chem. 279:2697-2703. (Pubitemid 38114258)
132. Simizu S, Suzuki T, Muroi M, Lai NS, Takagi S, Dohmae N, Osada H. 2007. Involvement of disulfide bond formation in the activation of heparanase. Cancer Res. 67:7841-7849. (Pubitemid 47281379)
133. Skolnick J, Brylinski M. 2009. FINDSITE: A combined evolution/structure- based approach to protein function prediction. Brief Bioinform. 10: 378-391.
134. Soding J, Biegert A, Lupas AN. 2005. The HHpred interactive server for protein homology detection and structure prediction. Nucl Acids Res. 33: W244-W248. (Pubitemid 44529917)
135. Stahl M, Rarey M. 2001. Detailed analysis of scoring functions for virtual screening. J Med Chem. 44:1035-1042. (Pubitemid 32852130)
136. Takaoka T, Mori K, Okimoto N, Neya S, Hoshino T. 2007. Prediction of the structure of complexes comprised of proteins and glycosaminoglycans using docking simulation and cluster analysis. J Chem Theory Comput. 3:2347-2356.
137. Taylor EJ, Smith NL, Turkenburg JP, D'Souza S, Gilbert HJ, Davies GJ. 2006. Structural insight into the ligand specificity of a thermostable family 51 arabinofuranosidase, Araf51, from Clostridium thermocellum. Biochem J. 395:31-37.
138. Thomas AH. 1996a. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 17:490-519.
139. Thomas AH. 1996b. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J Comput Chem. 17:520-552.
140. Thomas AH. 1996c. Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. J Comput Chem. 17:553-586.
141. Thomas AH, Robert BN. 1996. Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J Comput Chem. 17:587-615.
142. Thunberg L, Backstrom G, Wasteson A, Robinson HC, Ogren S, Lindahl U. 1982. Enzymatic depolymerization of heparin-related polysaccharides: Substrate specificities of mouse mastocytoma and human platelet endo-beta-D- glucuronidases. J Biol Chem. 257:10278-10282. (Pubitemid 13251026)
143. Tom D, Darrin Y, Lee P. 1993. Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. J Chem Phys. 98:10089-10092.
144. Varrot A, Schulein M, Fruchard S, Driguez H, Davies GJ. 2001. Atomic resolution structure of endoglucanase Cel5A in complex with methyl 4,4II,4III,4IV-tetrathio-alpha-cellopentoside highlights the alternative binding modes targeted by substrate mimics. Acta Crystallogr D Biol Crystallogr. 57:1739-1742. (Pubitemid 33037761)
145. Viktor H, Robert A, Asim O, Bentley S, Adrian R, Carlos S. 2006. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 65:712-725.
146. Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L, Shafat I, Ilan N. 2008. Heparanase: One molecule with multiple functions in cancer progression. Connect Tissue Res. 49:207-210.
147. Vlodavsky I, Friedmann Y. 2001. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 108:341-347. (Pubitemid 32730777)
148. Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, Naggi A, Torri G, Casu B, Sasisekharan R. 2007. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res. 120 (Suppl 2):S112-S120. (Pubitemid 350101779)
149. Vlodavsky I, Ilan N, Naggi A, Casu B. 2007. Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 13:2057-2073. (Pubitemid 47044735)
150. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M, Ishai-Michaeli R, Peretz T. 1994. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis. 14:290-302.
151. Warner CD, Hoy JA, Shilling TC, Linnen MJ, Ginder ND, Ford CF, Honzatko RB, Reilly PJ. 2010. Tertiary structure and characterization of a glycoside hydrolase family 44 endoglucanase from Clostridium acetobuty-licum. Appl Environ Microbiol. 76:338-346.
152. Woods RJ. 2005-2011. GLYCAM Web. Athens, GA: Woods Group. http://glycam.ccrc.uga.edu/ccrc/pages/3dspt.html.
153. Yang JK, Yoon HJ, Ahn HJ, Lee BI, Pedelacq JD, Liong EC, Berendzen J, Laivenieks M, Vieille C, Zeikus GJ, et al. 2004. Crystal structure of beta-D-xylosidase from Thermoanaerobacterium saccharolyticum, a family 39 glycoside hydrolase. J Mol Biol. 335:155-165. (Pubitemid 37494969)
154. Yu G, Gunay NS, Linhardt RJ, Toida T, Fareed J, Hoppensteadt DA, Shadid H, Ferro V, Li C, Fewings K, et al. 2002. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur J Med Chem. 37:783-791. (Pubitemid 35350842)
155. Zhang Y. 2008. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 9:40.
156. Zhang Y. 2009. I-TASSER: Fully automated protein structure prediction in CASP8. Proteins. 77 (Suppl 9):100-113.
157. Zhou Z, Bates M, Madura JD. 2006. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design. Proteins. 65:580-592. (Pubitemid 44583209)